SAMA and SABA + SAMA use associated with increased risk for heart failure, arrhythmia, and mortality versus no use ...
Labeling update reduces required post-infusion monitoring time for initial doses from 22 to 24 hours to 6 to 8 hours in patients with extensive-stage small cell lung cancer.
Progressive decrease in adjusted odds of hospitalization seen in association with vaccination versus no vaccination.
The NDA is supported by phase 3 LATITUDE data demonstrating rapid and durable skin clearance in adults with moderate to severe plaque psoriasis.